Everolimus Versus Temsirolimus in Metastatic Renal Cell Carcinoma After Progression With Previous Systemic Therapies
Shiven B. Patel(Huntsman Cancer Institute), Neeraj Agarwal(University of Utah), Srinivas K. Tantravahi(University of Utah), David D. Stenehjem(University of Utah), Archana M. Agarwal(University of Utah), Winston Vuong(City of Hope), David Gill(Intermountain Healthcare), Joanne I. Hsu(Brigham and Women's Hospital), Sumanta K. Pal(City of Hope)
Cited by 15
Related Papers
Nivolumab plus ipilimumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial
|Nature Medicine|2022|453
PPM1D Mutations Drive Clonal Hematopoiesis in Response to Cytotoxic Chemotherapy
|Cell stem cell|2018|423
BCR-ABL1 Compound Mutations Combining Key Kinase Domain Positions Confer Clinical Resistance to Ponatinib in Ph Chromosome-Positive Leukemia
|Cancer Cell|2014|366